Zacks Research Has Positive Forecast for BHC FY2025 Earnings

Bausch Health Cos Inc. (NYSE:BHC) – Zacks Research raised their FY2025 earnings per share estimates for shares of Bausch Health Cos in a note issued to investors on Wednesday, November 19th. Zacks Research analyst Team now forecasts that the company will earn $3.83 per share for the year, up from their previous estimate of $3.77. The consensus estimate for Bausch Health Cos’ current full-year earnings is $4.41 per share. Zacks Research also issued estimates for Bausch Health Cos’ Q1 2026 earnings at $0.82 EPS, Q2 2026 earnings at $0.92 EPS, Q3 2026 earnings at $1.09 EPS, Q4 2026 earnings at $1.05 EPS, FY2026 earnings at $3.88 EPS, Q1 2027 earnings at $0.77 EPS, Q2 2027 earnings at $0.95 EPS and Q3 2027 earnings at $1.02 EPS.

A number of other equities analysts have also recently commented on the stock. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Bausch Health Cos in a research note on Wednesday, October 8th. Wall Street Zen upgraded Bausch Health Cos from a “buy” rating to a “strong-buy” rating in a research report on Saturday, November 1st. Three research analysts have rated the stock with a Hold rating, Based on data from MarketBeat, Bausch Health Cos presently has an average rating of “Hold” and an average price target of $9.00.

Bausch Health Cos Trading Down 2.2%

BHC stock opened at $6.05 on Thursday. Bausch Health Cos has a twelve month low of $4.25 and a twelve month high of $8.69. The stock has a market capitalization of $2.24 billion, a price-to-earnings ratio of 23.25 and a beta of 0.47. The company has a quick ratio of 0.98, a current ratio of 1.31 and a debt-to-equity ratio of 141.90. The firm’s fifty day simple moving average is $6.50 and its two-hundred day simple moving average is $6.24.

Institutional Trading of Bausch Health Cos

Several institutional investors and hedge funds have recently modified their holdings of BHC. Private Management Group Inc. grew its stake in Bausch Health Cos by 13.8% in the first quarter. Private Management Group Inc. now owns 1,439,426 shares of the company’s stock worth $9,313,000 after purchasing an additional 174,176 shares in the last quarter. Federated Hermes Inc. bought a new position in shares of Bausch Health Cos during the 1st quarter worth $758,000. XTX Topco Ltd purchased a new position in shares of Bausch Health Cos during the first quarter valued at $139,000. Wealthquest Corp bought a new stake in shares of Bausch Health Cos in the first quarter valued at about $58,000. Finally, Cary Street Partners Financial LLC purchased a new stake in Bausch Health Cos in the first quarter worth about $27,000. Institutional investors own 78.65% of the company’s stock.

Bausch Health Cos Company Profile

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.